Xavier Golay, Ph.D.

Professor of MR Neurophysics and Translational Neuroscience

Xavier is a Professor of MRI Physics at UCL. He is the current CEO of GSP, and contributes over 20 years’ experience of R&D in the field of MRI, from new imaging techniques to the development of contrast agents. Xavier is originally from Switzerland. He started working on Arterial Spin Labelling during his PhD in the Mid ‘90s and eventually became one of the world’s most renowned MRI specialists in this field. In addition to his academic career, Xavier spent two years working for Philips Healthcare in Singapore. He is currently the Vice Dean for Enterprise of the Faculty of Brain Sciences and, as such, is in charge of facilitating technology transfer within the faculty, by means of IP licensing, consulting activities or establishment of spinout companies.
In the last four years, Xavier co-founded both Imgenious and Gold Standard Phantoms together with Aaron Oliver-Taylor and Tom Hampshire.
Xavier’s role is to oversee the whole operation at GSP and in particular to help providing the support and network necessary to such a small enterprise. He is leading on most legal and financial aspects of the business, and provides guidance to the whole team.

dont miss

Image-based biomarkers of disease progression in dementia: current and future prospects

With the emergence of potential new disease-modifying molecules and other treatments for dementia comes the necessity to assess its efficacy in a time-efficient manner. Traditional approval for medicine have relied on the use of clinical endpoints, often based on lengthy interviews of patients and other neurological assessments. The typical noise associated with the use of these clinical scales makes it difficult to detect subtle benefits of potential new treatments over a short time, and as such there is a need for the development of other assessment strategies. Biomarkers report directly on one aspect of the disease, and image-based biomarkers have seen a rapid development over the last decade as an important tool to diagnose dementia and follow its progression. From the original biomarkers based on the quantitative assessment of grey matter depletion, either within the hippocampus or the whole brain, a whole new series of advanced imaging techniques have been developed, all providing complementary information on the state and advancement of the disease, from estimate of functional connectivity to baseline perfusion levels, and from structural integrity to amyloid and other protein aggregation. In this presentation, I will summarise some of the most important work done on image-based biomarkers recently, in particular through the ongoing large-scale initiatives such as the Alzheimer''s Disease Neuroimaging Initiative (ADNI).